Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles

Journal of Microencapsulation

Volumn 30, Issue 1, 2013, Pages 10-20

  Şimşek, Soner ^a   Eroǧlu, Hakan ^a   Kurum, Bariş ^b   Ulubayram, Kezban ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Brain targeting; Nanoparticles; PLGA b PEG; Polysorbate 80

Indexed keywords

ATORVASTATIN; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYSORBATE 80;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CONCENTRATION (PARAMETERS); DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; ENDOTHELIUM CELL; NEUROLOGIC DISEASE; NONHUMAN; PARTICLE SIZE;

BRAIN; FLUORESCENT DYES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; PYRROLES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84871403165     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.692400     Document Type: Article

References (41)

1. Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlu N. Development and characterization of Cyclosporine A loaded nanoparti-cles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release, 2011;151:286-94.
2. Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target, 2005;13:535-42.
3. Bourquin C, Wurzenberger C, Heidegger S, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S. Delivery of immunostimu-latory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J Immunother, 2010;33:935-44.
4. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett, 2006;6:662-8.
5. Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med, 2010;16:561-73.
6. Duncan R. Polymer therapeutics as nanomedicines: New perspectives. Curr Opin Biotechnol, 2011;22:492-501.
7. Eroglu H, Nemutlu E, Turkoglu OF, Nacar O, Bodur E, Sargon MF, Beskonakli E, Oner L. A quadruped study on chitosan microspheres containing atorvastatin calcium: Preparation, characterization, quantification and in-vivo application. Chem Pharm Bull (Tokyo), 2010;58:1161-7.
8. Faucher L, Guay-Begin AA, Lagueux J, Côté MF, Petitclerc E, Fortin MA. Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging, 2011; 6(4):209-18.
9. Gaspar VM, Sousa F, Queiroz JA, Correia IJ. Formulation of chitosan-TPP-pDNA nanocapsules for gene therapy applications. Nanotechnology, 2011;22(1):1-12.
10. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nano-particles: Influence of the formulation parameters. Eur J Pharm Biopharm, 2010;74:157-63.
11. Greenspan P, Mayer EP, Fowler SD. Nile red: A selective fluorescent stain for intracellular lipid droplets. J Cell Biol, 1985;100:965-73.
12. Guo R, Zhang L, Qian H, Li R, Jiang X, Liu B. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy. Langmuir, 2010;26:5428-34.
13. Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci, 2010;13:472-85.
14. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 2010;31:3657-66.
15. Huynh NT, Roger E, Lautram N, Benoit JP, Passirani C. The rise and rise of stealth nanocarriers for cancer therapy: Passive versus active targeting. Nanomedicine (Lond), 2010;5:1415-33.
16. Kayal S, Ramanujan RV. Anti-cancer drug loaded iron-gold core-shell nanoparticles (Fe@Au) for magnetic drug targeting. J Nanosci Nanotechnol, 2010;10:5527-39.
17. Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol, 2012;7:62-8.
18. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 2001;47:65-81.
19. Kreuter J. 2005. Application of nanoparticles for the delivery of drugs to the brain, The International Congress Series of Drug Transport(ers) and the Diseased Brain, S'Agaro(Girano), Spain, Vol. 1277, pp. 85-94.
20. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysor-bate-80- coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res, 2003;20:409-16.
21. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J drug targeting, 2002;10:317-25.
22. Kuipers HF, van den Elsen PJ. Immunomodulation by statins: Inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother, 2007;61:400-7.
23. Kumar S, Harrison N, Richards-Kortum R, Sokolov K. Plasmonic nanosen-sors for imaging intracellular biomarkers in live cells. Nano Lett, 2007;7:1338-43.
24. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke, 2000;31:2442-9.
25. Lu D, Goussev A, Chen J, Pannu P, Li Y, Mahmood A, Chopp M. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma, 2004;21:21-32.
26. McKeon-Fischer KD, Freeman JW. Characterization of electrospun poly(L-lactide) and gold nanoparticle composite scaffolds for skeletal muscle tissue engineering. J Tissue Eng Regen Med, 2011;5(7):560-8.
27. Musyanovych A, Dausend J, Dass M, Walther P, Mailander V, Landfester K. Criteria impacting the cellular uptake of nanoparticles: A study emphasizing polymer type and surfactant effects. Acta Biomater, 2011;7:4160-8.
28. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng, 2007;9:257-88.
29. Patterson AJ, Tang TY, Graves MJ, Müller KH, Gillard JH. In vivo carotid plaque MRI using quantitative T(2)*measurements with ultrasmall superparamagnetic iron oxide particles: A dose-response study to statin therapy. NMR Biomed, 2011;24(1):89-95.
30. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007;2:751-60.
31. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci, 2000;12:1931-40.
32. Rosellini E. Barbani N, Giusti P, Ciardelli G, Cristallini C. Molecularly imprinted nanoparticles with recognition properties towards a laminin H-Tyr-Ile-Gly-Ser-Arg-OH sequence for tissue engineering applications. Biomed Mater, 2010;5(6):1-11.
33. Sandhu A, Handa H, Abe M. Synthesis and applications of magnetic nano-particles for biorecognition and point of care medical diagnostics. Nanotechnology, 2010;21:442001.
34. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides, 1998;19:777-80.
35. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg, 2004;101:104-7.
36. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging, 2002;6:324-31.
37. Turkoglu OF, Eroglu H, Okutan O, Gurcan O, Bodur E, Sargon MF, Oner L, Beskonakli E. Atorvastatin efficiency after traumatic brain injury in rats. Surg Neurol, 2009;72:146-52 (discussion 152).
38. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke, 1999;30:1969-73.
39. Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, Gu N, Zhang Y, Xu H, Xu H, Yang X. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials, 2011;32:495-502.
40. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002;420:78-84.
41. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther, 2008;83:761-9.